Brief: MorphoSys Q4 Consolidated Revenues Up At EUR 81.6 Mln

Morphosys AG

15/03/2023 20:01

March 16 (Reuters) - MORPHOSYS AG  MORG.DE :
    * SAID ON WEDNESDAY: MONJUVI NET PRODUCT SALES IN THE US OF
$25.3
MILLION (EUR 24.7 MILLION) FOR Q4 AND $89.4 MILLION (EUR 84.9
MILLION) FOR 2022
    * CONSOLIDATED REVENUES FOR Q4 OF €81.6 MILLION, UP 54%
    * IN Q4 COST OF SALES WAS €15.4 MILLION COMPARED TO €9.5
MILLION
YEAR AGO
    * IN 2022 COST OF SALES WAS €48.6 MILLION COMPARED TO €32.2
MILLION YEAR AGO
    * 2022 RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO €297.8
MILLION COMPARED TO €225.2 MILLION IN 2021
    * Q4 RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO €94.0
MILLION
COMPARED TO €87.0 MILLION YEAR AGO
    * CONSOLIDATED REVENUES FOR 2022 OF €278.3 MILLION COMPARED
TO
€179.6 MILLION IN 2021
    * Q4 OPERATING LOSS WAS €68.4 MILLION COMPARED TO A LOSS OF
€325.0
MILLION FOR THE SAME PERIOD IN 2021
    * FY OPERATING LOSS WAS €220.7 MILLION COMPARED TO AN
OPERATING
LOSS OF €508.3 MILLION IN 2021
    * Q4 CONSOLIDATED PROFIT WAS €329.4 MILLION COMPARED TO A
CONSOLIDATED LOSS OF €381.0 MILLION IN THE SAME PERIOD OF 2021
    * 2022 CONSOLIDATED LOSS WAS €151.1 MILLION COMPARED TO A
CONSOLIDATED LOSS OF €514.5 MILLION IN 2021
    * EXPECTS FULL PATIENT ENROLLMENT FOR THE PIVOTAL PHASE 3
STUDY
(MANIFEST 2) OF PELABRESIB IN MYELOFIBROSIS (MF) IN 2023 AND
SUBMISSION OF TOPLINE RESULTS IN EARLY 2024
    * EXPECTS DATA FROM PRIMARY ANALYSIS OF PHASE 3 STUDY
(INMIND)
WITH TAFASITAMAB IN PATIENTS WITH INDOLENT LYMPHOMA (R/R FL/MZL)
IN 2024
    * EXPECTS DATA OF THE PRIMARY ANALYSIS OF THE PIVOTAL PHASE
3
STUDY (FRONTMIND) WITH TAFASITAMAB IN PREVIOUSLY UNTREATED DLBCL
IN H2 2025
    * CASH AND OTHER FINANCIAL ASSETS OF €907.2 MILLION AS OF
DECEMBER
31, 2022
    * SEES 2023 MONJUVI NET PRODUCT SALES IN THE US OF $80-$95
MILLION
    * SEES 2023 GROSS MARGIN FOR US NET PRODUCT SALES FROM
MONJUVI OF
75% TO 80%
    * SEES 2023 RESEARCH AND DEVELOPMENT (RESEARCH AND
DEVELOPMENT)
EXPENSES OF €290 TO €315 MILLION
    * SEES 2023 SELLING, ADMINISTRATIVE AND GENERAL EXPENSES OF
€140
TO €155 MILLION

Further company coverage:  MORG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))